2. >>Innovation

Running Ahead of the Pack in Technology Development

Device companies have historically kept innovation simple, giving doctors new tools that look and feel very much like what they've used in the past. But what happens when device innovation runs ahead of customers' willingness to adopt new technology?

In so doing, VP sheds new light on nearly a century of thinking about what causes acute myocardial infarctions, particularly in asymptomatic patients. If the VP proponents are right, these people often suffer heart attacks not because plaque gradually builds up inside coronary arteries until blood flow is blocked, but because inflamed macrophages cause plaque to erode and suddenly erupt, releasing thrombus.

What's amazing is how quickly physicians are jumping on the VP bandwagon. Maybe it's just wishful thinking, but companies developing tools to detect and treat it insist that cardiologists are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

More from In Vivo